Original Study| Volume 31, ISSUE 3, P242-246, June 2018

Download started.


Gynecologic Bleeding Complications in Postmenarchal Female Adolescents Receiving Antithrombotic Medications

Published:December 20, 2017DOI:


      Study Objective

      The prevalence, clinical features, and management of gynecologic bleeding complications and health care provider awareness of these in postmenarchal adolescents receiving antithrombotic medications has rarely been addressed in the literature. We sought to address these issues in a review of our experience in a pediatric tertiary care center.

      Design, Setting, and Participants

      A retrospective chart review was conducted with institutional review board approval from 2004 to 2014, on eligible postmenarchal adolescents receiving antithrombotic medications. Descriptive statistics were used.


      Sixty-eight adolescents received antithrombotic medications (thromboembolism in 67 of 68; 99%; cardiac causes in 4 of 68; 6%), which included enoxaparin, warfarin, unfractionated heparin, alteplase, fondaparinux, and aspirin. Heavy menstrual bleeding (HMB) screening questions were documented by treating hematologists in 52 of 68 patients (76%; 95% confidence interval, 65%-86%). Adolescent gynecology consult was requested for 25 of 68 patients (37%). After antithrombotic medications were started, 13 of 68 (19%) developed HMB. Anemia was found in 43% of patients tested (18 of 42); 50% (9 of 18) and 78% patients (14 of 18) received packed red blood cell transfusion and iron therapy, respectively. Five patients (5 of 68; 7%) developed hemorrhagic ovarian cysts, 40% (2 of 5) were treated with surgery, 16% (1 of 5) received transfusions, and 100% (5 of 5) received or continued progesterone-only therapy with no recurrence.


      Adolescents receiving antithrombotic medications are at risk of developing gynecologic bleeding complications, which can result in anemia, hospitalization, transfusions, or surgery. Provider awareness/screening of HMB as a bleeding complication of antithrombotic medications is less than optimal. Future prospective studies in adolescents receiving antithrombotic medications are needed to better evaluate provider awareness and the prevalence of gynecologic bleeding complications, which can lead to effective management.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Pediatric and Adolescent Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Palareti G.
        • Cosmi B.
        Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients.
        Thromb Haemost. 2009; 2: 102
        • Dietrich J.E.
        • Srivaths L.
        Navigating hormones and gynecologic concerns among female adolescents in the settings of thrombophilia and anticoagulation.
        J Pediatr Adolesc Gynecol. 2015; 6: 28
        • Själander A.
        • Friberg B.
        • Svensson P.
        • et al.
        Menorrhagia and minor bleeding symptoms in women on oral anticoagulation.
        J Thromb Thrombolysis. 2007; 1: 24
        • Huq F.Y.
        • Tvarkova K.
        • Arafa A.
        • et al.
        Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation.
        Contraception. 2011; 2: 84
        • Castellino G.
        • Cuadrado M.J.
        • Godfrey T.
        • et al.
        Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment.
        Ann Rheum Dis. 2001; 5: 60
        • Martinelli I.
        • Lensing A.W.
        • Middeldorp S.
        • et al.
        Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
        Blood. 2016; 11: 127
        • Wilbur A.
        • Goldstein L.
        • Prywitch B.
        Hemorrhagic ovarian cysts in patients on anticoagulation therapy: CT findings.
        J Comput Assist Tomogr. 1993; 4: 17
        • Sonmezer M.
        • Atabekoglu C.
        • Cengiz B.
        • et al.
        Depot-medroxyprogesterone acetate in anticoagulated patients with previous hemorrhagic corpus luteum.
        Eur J Contracept Reprod Health Care. 2005; 1: 10
        • Peake L.
        • Grover S.
        • Monagle P.
        • et al.
        Effect of warfarin on menstruation and menstrual management of the adolescent on warfarin.
        J Paediatr Child Health. 2011; 12: 47
        • De Crem N.
        • Peerlinck K.
        • Vanassche T.
        • et al.
        Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists.
        Thromb Res. 2015; 4: 136
        • Ferreira M.
        • Barsam S.
        • Patel J.P.
        • et al.
        Heavy menstrual bleeding on rivaroxaban.
        Br J Haematol. 2016; 2: 173
        • Myers B.
        • Webster A.
        Heavy menstrual bleeding on rivaroxaban - comparison with apixaban.
        Br J Haematol. 2016; 5: 176
        • Culwell K.R.
        • Curtis K.
        Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a systematic review.
        Contraception. 2009; 4: 80
        • Pisoni C.N.
        • Cuadrado M.J.
        • Khamashta M.A.
        • et al.
        Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil).
        Lupus. 2006; 12: 15
        • Sokkary N.A.
        • Dietrich J.E.
        • Venkateswaran L.
        Idiopathic pulmonary hypertension causing acquired von Willebrand disease and menorrhagia.
        J Pediatr Adolesc Gynecol. 2011; 5: 24
        • Wasserlauf G.
        • Grandi S.M.
        • Filion K.B.
        • et al.
        Meta-analysis of rivaroxaban and bleeding risk.
        Am J Cardiol. 2013; 3: 112